Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm

Allogeneics Still Waiting For Breakthrough

Executive Summary

Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors. 

You may also be interested in...



KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts

Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.

Speculation Grows On Potential Big Pharma Buyout Of Mirati

Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.

Arvinas And Pfizer’s Protein Degrader Shows Mixed Results In Breast Cancer

The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel